As mRNA continues to enter and be adopted by the global healthcare community, the need to quickly validate and scale these ...

The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in ...

Seven in 10 U.S. hiring managers say their company usually considers employing overqualified applicants, according to a ...

While the threat of tariffs dies down for the pharma industry, President Donald Trump is reportedly weighing a new ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN ...

Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...

Novo Nordisk’s leadership gets another shake-up as President Trump promises to significantly slash prices for its GLP-1 drugs ...

The company cut back in areas while investing in internal and external opportunities to offset the loss of exclusivity on a ...

AI is changing the nature of leadership in biopharma. Here’s how executives can not only adapt, but lead the way.

With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for ...

The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation ...